**Table S1:** Clinical characteristics of all patients

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nr | Diagnosis group (Control, pneumonia, COVID-19) | Diagnosis | Age(rounded to 5 years interval) | Outcome1=survivor, 2=Deceased |
| 1 | Control  | Cholangiocarcinoma  | 75 | 1 |
| 2 | Control  | Pancreatic cancer  | 70 | 1 |
| 3 | Control  | Hepatocelullar carcinoma  | 70 | 1 |
| 4 | Control  | Crohn’s disease, small intestinal resection | 55 | 1 |
| 5 | Control  | Infection with uncertain focus  | 45 | 1 |
| 6 | Control  | Infrarenal aortic aneurysm  | 65 | 1 |
| 7 | Control  | Pancreatic cancer | 65 | 1 |
| 8 | Control  | Colorectal carcinoma | 50 | 1 |
| 9 | Control  | Hepatocelullar carcinoma  | 70 | 1 |
| 10 | Control  | Klatskin cancer | 55 | 1 |
| 11 | Control  | Liver resection, liver cirrhosis | 55 | 1 |
| 12 | Control  | Gastric carcinoma | 50 | 1 |
| 13 | Control  | Non-Hodgkin lymphoma  | 40 | 1 |
| 14 | Control  | Colorectal carcinoma | 60 | 1 |
| 15 | Control  | Gastric cancer | 90 | 1 |
| 16 | Control  | Gastric bypass | 50 | 1 |
| 17 | Control  | Prostate cancer  | 55 | 1 |
| 18 | Control  | Cholangiocarcinoma | 70 | 1 |
| 19 | Control  | Reconnection operation after Hartmann-Operation | 60 | 1 |
| 20 | Control  | Cholecystectomy  | 45 | 1 |
| 21 | Control  | Colorectal carcinoma | 70 | 1 |
| 22 | Control  | Hepatocelullar carcinoma | 80 | 1 |
| 23 | Control  | Perforated gastric ulcer | 70 | 1 |
| 24 | Control  | Colon carcinoma with hepatic metastasis  | 60 | 1 |
| 25 | Control  | Colon carcinoma | 60 | 1 |
| 26 | Control  | Whipple`s operation, papillary carcinoma  | 70 | 1 |
| 27 | Pneumonia  | - | 45 | 1 |
| 28 | Pneumonia | - | 55 | 1 |
| 29 | Pneumonia | - | 70 | 1 |
| 30 | Pneumonia | Influenza | 70 | 1 |
| 31 | Pneumonia |  | 70 | 1 |
| 32 | Pneumonia | Influenza | 70 | 1 |
| 33 | Pneumonia | - | 65 | 1 |
| 34 | Pneumonia | Aspiration pneumonia  | 95 | 2 |
| 35 | Pneumonia | - | 80 | 2 |
| 36 | Pneumonia | - | 75 | 1 |
| 37 | Pneumonia | - | 70 | 1 |
| 38 | Pneumonia | - | 65 | 1 |
| 39 | Pneumonia | - | 75 | 1 |
| 40 | Pneumonia | - | 70 | 2 |
| 41 | Pneumonia | - | 85 | 1 |
| 42 | Pneumonia | AIDS | 55 | 1 |
| 43 | Pneumonia | - | 60 | 1 |
| 44 | Pneumonia | - | 40 | 1 |
| 45 | Pneumonia | - | 70 | 1 |
| 46 | Pneumonia | - | 35 | 1 |
| 47 | Pneumonia | - | 65 | 1 |
| 48 | Pneumonia | - | 60 | 1 |
| 49 | Pneumonia | - | 35 | 1 |
| 50 | COVID-19 | COVID-19 | 85 | 2 |
| 51 | COVID-19 | COVID-19 | 50 | 1 |
| 52 | COVID-19 | COVID-19 | 70 | 2 |
| 53 | COVID-19 | COVID-19 | 25 | 1 |
| 54 | COVID-19 | COVID-19 | 70 | 1 |
| 55 | COVID-19 | COVID-19 | 85 | 1 |
| 56 | COVID-19 | COVID-19 | 60 | 2 |
| 57 | COVID-19 | COVID-19 | 90 | 1 |
| 58 | COVID-19 | COVID-19 | 90 | 1 |
| 59 | COVID-19 | COVID-19 | 80 | 1 |
| 60 | COVID-19 | COVID-19 | 75 | 1 |
| 61 | COVID-19 | COVID-19 | 50 | 1 |
| 62 | COVID-19 | COVID-19 | 65 | 1 |
| 63 | COVID-19 | COVID-19 | 40 | 1 |
| 64 | COVID-19 | COVID-19 | 55 | 1 |
| 65 | COVID-19 | COVID-19 | 75 | 2 |
| 66 | COVID-19 | COVID-19 | 80 | 1 |
| 67 | COVID-19 | COVID-19 | 30 | 1 |
| 68 | COVID-19 | ARDS by COVID-19 | 60 | 2 |
| 69 | COVID-19 | COVID-19 | 60 | 1 |
| 70 | COVID-19 | COVID-19 | 80 | 2 |
| 71 | COVID-19 | COVID-19 | 80 | 1 |
| 72 | COVID-19 | COVID-19 | 70 | 1 |
| 73 | COVID-19 | COVID-19 | 90 | 1 |
| 74 | COVID-19 | COVID-19 | 15 | 1 |
| 75 | COVID-19 | ARDS by COVID-19 | 55 | 2 |
| 76 | COVID-19 | ARDS by COVID-19 | 55 | 1 |
| 77 | COVID-19 | ARDS by COVID-19 | 65 | 1 |
| 78 | COVID-19 | ARDS by COVID-19 | 65 | 1 |
| 79 | COVID-19 | ARDS by COVID-19 | 50 | 2 |
| 80 | COVID-19 | ARDS by COVID-19 | 85 | 2 |
| 81 | COVID-19 | ARDS by COVID-19 | 50 | 1 |
| 82 | COVID-19 | ARDS by COVID-19 | 70 | 2 |
| 83 | COVID-19 | ARDS by COVID-19 | 55 | 1 |
| 84 | COVID-19 | ARDS by COVID-19 | 60 | 2 |

**Table S2: Correlation of TISS and SAPS scores with biomarkers.** Upper line – Pearson’ R, lower line 2-sided significance

|  |  |  |
| --- | --- | --- |
|  | Pneumonia | COVID-19 |
| Analyte | SAPS | TISS | SAPS | TISS |
| IL-8 | ***0.592******0.003*** | 0.2460.258 | 0.1310.684 | 0.0560.864 |
| IL-17 | ***0.517******0.012*** | 0.2340.283 | -0.2090.514 | -0.0680.833 |
| IL-18 | ***0.541******0.008*** | 0.2540.249 | 0.1190.514 | -0.0680.833 |
| MIP-1a | ***0.472******0.023*** | -0.1540.484 | 0.2820.374 | 0.2830.373 |
| MIP-1b | ***0.481******0.020*** | 0.1020.642 | -0.0220.946 | -0.0940.771 |
| MCP-1 | ***0.437******0.037*** | 0.010.963 | 0.020.95 | -0.1450.653 |
| VCAM-1 | ***0.457******0.028*** | 0.1260.568 | 0.3040.336 | -0.1290.69 |
| CA-9 | ***0.534******0.009*** | 0.0760.73 | 0.4560.136 | -0.0060.985 |
| CRP | 0.1620.46 | ***0.451******0.031*** | 0.0170.96 | 0.3740.257 |
| LP(a) | 0.230.292 | ***-0.466******0.025*** | -0.5730.052 | -0.4770.117 |
| Myoglobin | 0.1270.564 | ***0.428******0.042*** | 0.230.473 | -0.0070.982 |
| AFP | 0.150.494 | ***0.571******0.004*** | 0.1330.68 | ***0.704******0.011*** |
| ANG-1 | -0.0740.739 | -0.1720.433 | ***-0.587******0.045*** | -0.2180.495 |
| CEA | ***0.474******0.022*** | 0.220.313 | 0.4850.11 | -0.0550.865 |
| Thromb | -0.3690.084 | 0.0270.903 | ***0.735******0.01*** | ***-0.631******0.038*** |
| Krea | 0.0830.708 | -0.0610.783 | ***0.685******0.02*** | 0.0590.862 |
| Urea | 0.2140.327 | 0.1140.605 | ***0.634******0.036*** | 0.0580.862 |
| B2M | 0.3810.073 | -0.020.927 | ***0.779******0.003*** | 0.290.361 |
| C3 | ***-0.460******0.027*** | 0.0440.84 | ***-0.857******< 0.0001*** | -0.2760.385 |
| HCC-4 | 0.0030.989 | 0.2580.235 | ***0.641******0.034*** | 0.1590.622 |
| MMP-1 | 0.30.164 | 0.0230.917 | -***0.611******0.035*** | -0.5430.068 |
| MMP-7 | 0.1680.143 | ***0.505******0.014*** | 0.2990.345 | 0.2470.44 |
| MMP-9 | -0.2790.197 | -0.1650.451 | ***-0.740******0.006*** | -0.1660.607 |
| ICAM-1 | ***0.584******0.003*** | 0.3470.105 | -0.3940.205 | -0.2060.521 |
| SP-D | ***0.418******0.047*** | 0.0280.9 | 0.1210.708 | 0.0620.848 |
| Age | 0.0350.888 | -0.3080.153 | 0.4070.189 | 0.2680.4 |